Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11
Licensing Agreements 12
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12
Equity Offering 13
Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13
Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15
Celsus Therapeutics Completes Public Offering Of American Depositary Shares For US$8 Million 17
Celsus Therapeutics Completes Private Placement Of Shares For US$12.5 Million 19
Morria Biopharma Completes Private Placement Of Shares For US$0.8 Million 20
Morria Biopharma Completes Private Placement Of Units For US$1.5 Million 21
Acquisition 22
Celsus Therapeutics Acquires Volution Immuno Pharma 22
Akari Therapeutics Plc – Key Competitors 23
Akari Therapeutics Plc – Key Employees 24
Akari Therapeutics Plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Sep 27, 2018: Akari announces second quarter 2018 financial results and business highlights 26
Aug 17, 2018: Akari announces first quarter 2018 financial results and update on its growing pipeline of phase II and phase III clinical trials 27
Mar 21, 2018: Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress 29
Corporate Communications 31
May 08, 2018: Akari Therapeutics: Resignation of CEO 31
Jan 23, 2018: Akari Therapeutics Strengthens Board with Two Senior Industry Appointments 32
Aug 21, 2017: Akari Therapeutics Announces Appointment of David Horn Solomon as CEO 33
May 30, 2017: Akari Therapeutics Announces Resignation of CEO 34
Product Approvals 35
Mar 30, 2017: Akari Therapeutics Announces FDA Fast Track Designation For Coversin 35
Clinical Trials 36
Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association 36
Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials 37
Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint 38
Oct 11, 2017: Akari Therapeutics Announces Further Clinical Progress 39
Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 40
Apr 27, 2017: Akari Therapeutics Announces Edisons Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II” 41
Apr 24, 2017: Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets 42
Jan 03, 2017: Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12
Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13
Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15
Celsus Therapeutics Completes Public Offering Of American Depositary Shares For US$8 Million 17
Celsus Therapeutics Completes Private Placement Of Shares For US$12.5 Million 19
Morria Biopharma Completes Private Placement Of Shares For US$0.8 Million 20
Morria Biopharma Completes Private Placement Of Units For US$1.5 Million 21
Celsus Therapeutics Acquires Volution Immuno Pharma 22
Akari Therapeutics Plc, Key Competitors 23
Akari Therapeutics Plc, Key Employees 24
Akari Therapeutics Plc, Other Locations 25
Akari Therapeutics Plc, Subsidiaries 25
List of Figures
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9